| 國立成功大學 |
2023 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
|
Chan, A.T.C.;Lee, V.H.F.;Hong, R.-L.;Ahn, M.-J.;Chong, W.Q.;Kim, S.-B.;Ho, G.F.;Caguioa, P.B.;Ngamphaiboon, Ngamphaiboon N.;Ho, C.;Aziz, M.A.S.A.;Ng, Q.S.;Yen, C.-J.;Soparattanapaisarn, N.;Ngan, R.K.-C.;Kho, S.K.;Tiambeng, M.L.A.;Yun, T.;Sriuranpong, V.;Algazi, Algazi A.P.;Cheng, A.;Massarelli, E.;Swaby, R.F.;Saraf, Saraf S.;Yuan, J.;Siu, L.L. |
| 國立成功大學 |
2023 |
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Razak, A.R.A.;Wang, H.-M.;Chang, J.-Y.;Ahn, M.-J.;Munster, P.;Blumenschein, G.;Jr;Solomon, B.;Lim, D.W.-T.;Hong, R.-L.;Pfister, D.;Saba, N.F.;Lee, S.-H.;van, Herpen C.;Quadt, C.;Bootle, D.;Blumenstein, L.;Demanse, Demanse D.;Delord, J.-P. |
| 臺大學術典藏 |
2022-09-06T08:57:05Z |
Overexpression of p53 predicts shorter survival in diffuse type gastric cancer
|
Lee W.-J.; Shun C.-T.; Hong R.-L.; MING-SHIANG WU; Chang K.-J.; Chen K.-M. |
| 臺大學術典藏 |
2022-09-06T08:56:49Z |
Alterations of BAT-26 identify a subset of gastric cancer with distinct clinicopathologic features and better postoperative prognosis
|
MING-SHIANG WU; Lee C.-W.; Sheu J.-C.; Shun C.-T.; Wang H.-P.; Hong R.-L.; Lee W.-J.; Lin J.-T. |
| 臺大學術典藏 |
2022-08-23T02:35:03Z |
Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; SUNG-HSIN KUO; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2022-08-19T00:21:13Z |
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate
|
Lin C.-H.; Yen R.-F.; Jeng Y.-M.; Tzen C.-Y.; CHIUN HSU; Hong R.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.; Chang D.-Y.; Hu F.-C.; Shao Y.-Y.; CHIUN HSU; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-12T06:29:09Z |
A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers
|
Yeh K.-H.; Cheng A.-L.; Lin M.-T.; Hong R.-L.; Hsu C.-H.; Lin J.-F.; KING-JEN CHANG; Lee P.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2022-08-12T06:29:04Z |
Overexpression of p53 predicts shorter survival in diffuse type gastric cancer
|
Lee W.-J.; Shun C.-T.; Hong R.-L.; Wu M.-S.; KING-JEN CHANG; Chen K.-M. |
| 臺大學術典藏 |
2022-06-27T07:07:42Z |
The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients
|
Yen R.-F.; Chen C.-Y.; Cheng M.-F.; Wu Y.-W.; Shiau Y.-C.; Wu K.; Hong R.-L.; CHONG-JEN YU; Wang K.-L.; Yang R.-S. |
| 臺大學術典藏 |
2022-06-10T06:11:10Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
Yang S.-H.; Lin C.-C.; ZHONG-ZHE LIN; Tseng Y.-L.; Hong R.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:08Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
ZHONG-ZHE LIN; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2022-05-05T09:10:38Z |
Quality of life in patients of nasopharyngeal carcinoma: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35
|
WEI-CHU CHIE; Hong R.-L.; Lai C.-C.; Ting L.-L.; Hsu M.-M. |
| 臺大學術典藏 |
2022-05-05T08:48:57Z |
Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma
|
Hong R.-L.; Ting L.-L.; Ko J.-Y.; Hsu M.-M.; Sheen T.-S.; Lou P.-J.; CHIA-CHUN WANG; Chung N.-N.; Lui L.T. |
| 臺大學術典藏 |
2022-05-05T08:48:57Z |
Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5 fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: A phase II study
|
Hong R.L.; Sheen T.S.; Ko J.Y.; Hsu M.M.; CHIA-CHUN WANG; Ting L.L. |
| 臺大學術典藏 |
2022-04-26T07:24:38Z |
A Clinicopathological Study of Cytomegalovirus Lymphadenitis and Tonsillitis and Their Association with Epstein�VBarr Virus
|
Yu S.-C.; KUAN-YIN KO; Teng S.-C.; Huang T.-C.; Lo H.-T.; Cheng C.-L.; Yao M.; Hong R.-L.; Chen C.-N.; Chen T.-C.; Yang T.-L. |
| 臺大學術典藏 |
2022-04-25T07:36:11Z |
Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; JIA-HAU LIU; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; Kuo S.-H.; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2022-04-21T06:51:36Z |
Early restaging whole-body 18F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma
|
Yen R.-F.; Chen, Tony Hsiu Hsi; Ting L.-L.; Tzen K.-Y.; Pan M.-H.; Hong R.-L. |
| 臺大學術典藏 |
2022-04-21T06:51:35Z |
Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma
|
Yen R.-F.; Hong R.-L.; Tzen K.-Y.; Pan M.-H.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-21T06:51:10Z |
The Cost-utility Analysis of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography in the Diagnosis of Recurrent Nasopharyngeal Carcinoma
|
Yen R.-F.; Yen M.-F.; Hong R.-L.; Tzen K.-Y.; Chien C.-R.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-15T03:14:17Z |
Clinical and functional characterization of a novel STUB1 frameshift mutation in autosomal dominant spinocerebellar ataxia type 48 (SCA48)
|
Yu S.-C.; Ko K.-Y.; SHU-CHUN TENG; Huang T.-C.; Lo H.-T.; Cheng C.-L.; Yao M.; Hong R.-L.; Chen C.-N.; Chen T.-C.; Yang T.-L. |
| 臺大學術典藏 |
2022-04-14T07:20:22Z |
Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; FENG-MING TIEN; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; Kuo S.-H.; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2022-03-08T03:44:07Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
SHIH-HUNG YANG; Lin C.-C.; Lin Z.-Z.; Tseng Y.-L.; Hong R.-L. |
| 臺大學術典藏 |
2022-03-04T06:53:40Z |
Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate–cysteine ligase catalytic subunit in head and neck squamous cell carcinoma
|
Liu C.-W.; Hua K.-T.; Li K.-C.; Kao H.-F.; Hong R.-L.; Ko J.-Y.; Hsiao M.; Kuo M.-L.; CHING-TING TAN |
| 臺大學術典藏 |
2022-03-04T05:33:54Z |
Relation between Histological Intensity of Transforming Growth Factor-β Isoforms in Human Osteosarcoma and the Rate of Lung Metastasis
|
Yang R.-S.; CHEN-TU WU; Lin K.-H.; Hong R.-L.; Liu T.-K.; Lin K.-S. |
